Architectural Refuges: Mapping Spatial Heterogeneity and Niche-Mediated Drug Resistance in Gastric and Esophageal Adenocarcinomas
Cancers · 27.05.2026 · 18 (11) · 1748
DOI: 10.3390/cancers18111748 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.05.2026. Verfasst von Krishnapriya Thangaretnam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Florida Department of Health, Gastric Cancer Foundation, The Mark Foundation for Cancer Research.
Abstract (Originalsprache)
Resistance to systemic therapy remains the defining challenge in the management of gastric cancer (GC) and esophageal adenocarcinoma (EAC). While genomic drivers of resistance are well characterized, traditional bulk profiling has failed to capture the physical rules governing tumor survival within the complex tissue ecosystem. Emerging data from 2024–2025, leveraging high-resolution spatial transcriptomics and multi-omics, have recontextualized resistance as a phenomenon of “spatial privilege” rather than solely an intrinsic cellular fate. This review summarizes recent evidence to define “architectural refuges”: distinct spatial niches that physically shield malignant clones from cytotoxic and targeted agents. We delineate three critical resistance domains common to upper gastrointestinal adenocarcinomas: (1) The “Excluded” Niche, where specific cancer-associated fibroblast (CAF) subpopulations (iCAFs vs. myCAFs) and stiffened extracellular matrix create hypovascular zones that limit drug delivery; (2) the “Immune-Tolerant” Niche, characterized by the spatial exclusion of CD8+ T cells and the recruitment of suppressive myeloid populations via the MIF/CD74 and USP14 axes; and (3) the “Metabolic” Niche, where mitochondrial heterogeneity and lipid metabolic symbiosis establish nutrient-deprived niches that select for stem-like, dormant states. By mapping these conserved spatial determinants from primary GEJ tumors to peritoneal and distant metastases, we argue that overcoming resistance requires an advancement: moving beyond targeting individual mutations to dismantling the multicellular architecture that sustains malignancy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.
- Department of Veterans Affairs, Miami Healthcare System, Miami, FL 33125, USA.
ORCID-Profile: Krishnapriya Thangaretnam, Md Obaidul Islam, Jialun Lv, Lei Chen, Farah Ballout, Heng Lu, Dunfa Peng, Wael El-Rifai, Zheng Chen
Förderung
- Florida Department of Health
- Gastric Cancer Foundation
- The Mark Foundation for Cancer Research
- DeGregorio Family Foundation
- MARK foundation ASPIRE Award
- National Institutes of Health
- NCI Cancer Center Support Grant
Zitieren
APA
Thangaretnam, K., Islam, M. O., Lv, J., Chen, L., Ballout, F., Zhu, S., Lu, H., Peng, D., El-Rifai, W., & Chen, Z. (2026). Architectural Refuges: Mapping Spatial Heterogeneity and Niche-Mediated Drug Resistance in Gastric and Esophageal Adenocarcinomas. Cancers, 18(11), 1748. https://doi.org/10.3390/cancers18111748
Vancouver
Thangaretnam K, Islam MO, Lv J, Chen L, Ballout F, Zhu S, et al. Architectural Refuges: Mapping Spatial Heterogeneity and Niche-Mediated Drug Resistance in Gastric and Esophageal Adenocarcinomas. Cancers. 2026;18(11):1748. doi:10.3390/cancers18111748
BibTeX
@article{Thangaretnam2026,
author = {Thangaretnam, Krishnapriya and Islam, Md Obaidul and Lv, Jialun and Chen, Lei and Ballout, Farah and Zhu, Shoumin and Lu, Heng and Peng, Dunfa and El-Rifai, Wael and Chen, Zheng},
title = {Architectural Refuges: Mapping Spatial Heterogeneity and Niche-Mediated Drug Resistance in Gastric and Esophageal Adenocarcinomas},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1748},
doi = {10.3390/cancers18111748}
}
EUVIMED